SCHEMBL3133533

SCHEMBL3133533

N[C@@H](Cc1ccccc1)C(=O)N1CCC(O)CC1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 2/20 0.65
HDAC8 Q9BY41 3/20 0.62
DPP4 P27487 4/20 0.58
POLB P06746 1/20 0.57
DPP8 Q6V1X1 2/20 0.55
DPP9 Q86TI2 2/20 0.55
DPP7 Q9UHL4 2/20 0.55
FAP Q12884 1/20 0.55
OPRK1 P41145 1/20 0.54
SMYD3 Q9H7B4 1/20 0.54
TACR1 P25103 1/20 0.53
PLAU P00749 1/20 0.52
PLAUR Q03405 1/20 0.52
AKT1 P31749 1/20 0.52
AKT2 P31751 1/20 0.52
AKT3 Q9Y243 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6161830 1.00 OPRD1 (0.65) OPRD1HDAC8DPP4POLBDPP8
Hydrochloric Acid SCHEMBL6165745 0.99 HDAC8 (0.63) OPRD1HDAC8DPP4POLBDPP8
Hydrochloric Acid SCHEMBL6163301 0.99 HDAC8 (0.63) OPRD1HDAC8DPP4POLBDPP8
Hydrochloric Acid SCHEMBL6163295 0.99 HDAC8 (0.63) OPRD1HDAC8DPP4POLBDPP8
SCHEMBL4086820 0.92 HDAC8 (0.59) OPRD1HDAC8DPP4POLBDPP8
SCHEMBL4095232 0.92 HDAC8 (0.59) OPRD1HDAC8DPP4POLBDPP8
SCHEMBL6052747 0.92 HDAC8 (0.59) OPRD1HDAC8DPP4POLBDPP8
SCHEMBL7371920 0.88 NPC1 (0.58) OPRD1HDAC8DPP4DPP8DPP9
SCHEMBL7360693 0.87 HPGD (0.66) OPRD1HDAC8DPP4POLBDPP8
SCHEMBL2375481 0.86 OPRK1 (0.71) OPRD1HDAC8DPP4POLBOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1088824-B1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PFIZER PROD INC (US) 2004-01-07 EP claimed
US-20030195361-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PFIZER INC. 2003-10-16 US claimed
US-20020183369-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors DU BOIS DAISY JOE (US) 2002-12-05 US claimed
US-6399601-B1 ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS PFIZER INC. 2002-06-04 US claimed
EP-1088824-A2 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-04-04 EP claimed
US-20150050371-A1 Extract Formulations of Rhodamnia Cinerea And Uses Thereof BIOTROPICS MALAYSIA BERHAD (MY) 2015-02-19 US disclosed
WO-2013133685-A1 EXTRACT FORMULATIONS OF RHODAMNIA CINEREA AND USES THEREOF BIOTROPICS MALAYSIA BERHAD (MY) 2013-09-12 WO disclosed
EP-1636224-B1 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE PROSIDION LTD (GB) 2010-07-14 EP disclosed
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PROSIDION LIMITED (GB) 2009-01-22 US disclosed
US-7405210-B2 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase OSI PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE BRADLEY STUART E 2007-10-18 US disclosed
EP-1157695-B1 Method of treating obesity using a neurotensin receptor ligand PFIZER PROD INC (US) 2006-06-28 EP disclosed
EP-1134213-A2 Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides PFIZER INC. (US) 2001-09-19 EP disclosed
EP-1127882-A1 Tetrazole compounds as thyroid receptor ligands Pfizer Products Inc. (US) 2001-08-29 EP disclosed
EP-1125580-A2 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-08-22 EP disclosed
US-6277877-B1 GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS PFIZER, INC. 2001-08-21 US disclosed
EP-1088824-A2 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors Pfizer Products Inc. (US) 2001-04-04 EP disclosed
US-6107329-A HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS PFIZER, INC. (US) 2000-08-22 US disclosed
EP-0832065-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER INC. (US) 1998-04-01 EP disclosed
WO-1996039384-A1 SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS PFIZER, INC. (US) 1996-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195361-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PYGL, GYS1, PYGM OPRD1 2009/4885HDAC8 1108/4885DPP4 148/4885
US-20070244090-A9 PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE PYGL, PYGM, PYGB OPRD1 3457/4885HDAC8 1898/4885DPP4 226/4885
US-20090023703-A1 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase PYGL, PYGM, PYGB OPRD1 3457/4885HDAC8 1898/4885DPP4 226/4885
US-20020183369-A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors PYGL, PYGM, PYGB OPRD1 3310/4885HDAC8 1061/4885DPP4 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.